CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 18, 2019-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 3, 2019-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on April 1, 2019 , the Compensation Committee of Sage’s

Approval based on results from three pivotal trials showing treatment with ZULRESSO provided significant and rapid reduction of depressive symptoms within days Postpartum depression is the most common medical complication of childbirth, estimated to affect approximately 400,000 women annually in

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 5, 2019-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on March 1, 2019 , the Compensation Committee of Sage’s

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 27, 2019-- Sage Therapeutics (Nasdaq: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the closing of its previously announced underwritten public

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 25, 2019-- Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of 3,333,334

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 25, 2019-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that it has commenced an underwritten public offering of

Planned U.S. commercial launch of ZULRESSO™ (brexanolone) injection, if approved, on track for June 2019 , based on PDUFA target date of March 19, 2019 and anticipated DEA scheduling Topline data from Phase 3 trial of SAGE-217 in MDD expected in Q4 2019 or 1Q 2020 Neurology and neuropsychiatry

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 7, 2019-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on February 1, 2019 , the Compensation Committee of Sage’s

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 5, 2019-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on